PYRIDINIL- AND PYRAZINYL(AZA)INDOLSULFONAMIDES Russian patent published in 2023 - IPC C07D401/12 C07D403/12 C07D471/04 A61K31/4439 A61K31/506 A61P25/00 

FIELD: pharmaceutical chemistry.

SUBSTANCE: group of inventions includes a compound of formula I, its pharmaceutically acceptable salts, a method for treating multiple sclerosis, and a therapeutic composition. In formula I, X1 is N or C(R7), R2 and R4 are both hydrogen, R5 is hydrogen or halogen, R6 is selected from the group consisting of halogen, cyano, benzyloxy, C₁-C₃-alkoxy and C₁-C₃-alkyl, where each of the following: alkyl and alkoxy group, may contain one to three halogens, or R6 together with R7 and with the C atoms to which they are attached, form a 5- or 6-membered aromatic or non-aromatic ring, which may contain 1 or 2 ring-forming N-atoms, wherein said ring is unsubstituted, R7, if present, is selected from the group consisting of hydrogen and halogen, or R7 together with R6 form a ring as described above, R8 is selected from the group consisting of hydrogen, halogen, methoxy, ethoxy, fluoromethoxy and fluoroethoxy, R10 is selected from the group consisting of hydrogen, cyano, halogen, C₃-C₅-cycloalkyl, C₁-C₄-alkoxy and C₁-C₄-alkyl, where each of the following: alkyl and alkoxy group, may have one to three substituents selected from the group consisting of halogen and fluoro(C₁-C₃)alkoxy, R11 is selected from the group consisting of hydrogen, fluorine and methoxy, X2 is N or C(R12), R12 is selected from the group consisting of hydrogen, methoxy and halogen.

EFFECT: compound of formula I with GPR17 inhibitory activity, used for the treatment of multiple sclerosis.

23 cl, 1 dwg, 6 tbl

I